34 results on '"Kaneda, Hiroyasu"'
Search Results
2. Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study
3. The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer
4. The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
5. P28-11 The therapeutic efficacy of osimertinib in non-small cell lung cancer with malignant pleural effusion
6. MO16-3 Results of the first survey using EORTC QLQ INFO25 on information acquisition and satisfaction of lung cancer patients
7. Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations
8. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
9. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
10. Effects of Dose Modifications on Safety and Efficacy of Dacomitinib for EGFR+ NSCLC in ARCHER 1050 Japanese Subset
11. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
12. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
13. Clinical Response to Everolimus of EGFR–Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs
14. P2.06-015 The NICE Salvage Study: A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer
15. P3.02a-005 The Association between the Percentage of Anaplastic Lymphoma Kinase(ALK)-Positive Cells and Efficacy of ALK Inhibitor
16. Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib
17. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation
18. An autopsy case of thyroid cancer in a patient who died from perforative peritonitis during lenvatinib therapy
19. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
20. Immune-related response kinetics in patient with melanoma receiving nivolumab, programmed cell death 1 (PD-1) inhibitor
21. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer
22. Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer
23. Tumor Genomic Profiling of Nsclc From the Phase III Trial of First-Line S-1/Cbdca Versus Paclitaxel/Cbdca (Wjog6611Ltr)
24. Clinical Benefit of Continued Therapy with Crizotinib Beyond Initial Disease Progression in Advanced Alk Positive Nsclc
25. Heregulin as a Biomarker for Anti-Her3 Antibody Patritumab Combined with Erlotinib in Non-Small Cell Lung Cancer
26. Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement–Positive Non–Small-Cell Lung Cancer
27. P-0117 Second-Line Chemotherapy with S-1 after Cisplatin and Gemcitabine Failure in Patients with Advanced Biliary Tract Cancer
28. P-0118 Chemotherapy with Cpt-11 After Gemcitabine Failure in Patients with Advanced Pancreatic Cancer
29. A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer
30. Pharmacokinetics of Docetaxel in a Patient with Non-small Cell Lung Cancer Undergoing Continuous Ambulatory Peritoneal Dialysis
31. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure
32. Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401)
33. Large Cell Neuroendocrine Carcinoma of the Mediastinum with α-Fetoprotein Production
34. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.